iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin bags USFDA approval for Obeticholic Acid Tablets

1 Jun 2023 , 11:52 AM

Lupin Limited announced that it has received the United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application for Obeticholic Acid Tablets. The tablets are available in 5mg and 10mg variants and are the generic equivalent of Ocaliva Tablets of Intercept Pharmaceuticals, Inc.

Lupin plans to manufacture the said product at its Nagpur Facility in India.

As per IQVIA MAT Mar 2023 data, Obeticholic Acid Tablets (RLD Ocaliva) has estimated annual sales of USD 262 million in the United States.

In FY23, Lupin invested 7.90% of its revenue in research and development.

Lupin is a leader in anti-diabetic, cardiovascular, and respiratory segments and marks a significant presence in the anti-defective, gastrointestinal (GI), women’s health areas, and central nervous system (CNS).

Lupin operates 15 manufacturing sites, and 7 research centers. Further, it manages over 20,000 talent heads globally.

At around 11.49 AM, Lupin was trading 1.04% higher at Rs 812.85, against the previous close of Rs 804.50 on NSE. The counter touched an intraday high and low of Rs 817.35 and Rs 805 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Lupin
  • Lupin News
  • Lupin Updates
  • Lupin USFDA Approval
  • Pharma news
  • USFDA approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.